- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02489994
Performance of the ePrime System for Cellulite
Clinical Study to Evaluate the Performance of the ePrime System for the Treatment of Cellulite
Study Overview
Detailed Description
Up to 60 healthy adult volunteers seeking cellulite treatment, females of 25 to 60 years of age, from multiple investigational sites.
This is an open-label, multi-center study. Subjects in this study will receive a single subcutaneous treatment with the ePrime device in one treatment session according to the study protocol.
Prior to treatments, tissue to be treated will be injected with tumescence or local dermal infiltration solution according to the protocol. Subjects will return for follow-up (FU) visits at: 1 week, 1 month, 3 months and 6 months following the treatment.
Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33133
- Bowes Leyda
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- David Goldberg
-
-
New York
-
New York, New York, United States, 10028
- Macrene Alexiades
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28270
- Girish Munavalli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects seeking treatment of cellulite in the upper thighs and buttocks areas.
- Subject have cellulite stage II or III as graded using Nurnberger-Muller scale clasification (Appendix III)
- Healthy female subjects ages 25 to 60 years of age
- Informed consent process completed and subject signed consent
- Willing to receive the proposed ePrime treatment and follow-up protocol
- Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence)
- Willing to have photographs taken of the treated areas to be used de-identified in evaluations, publications and presentations
Exclusion Criteria:
- Subject had surgery or any other procedure for cellulite in the last 6 months
- Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding
- Known allergy to lidocaine or epinephrine or antibiotics
- Active malignancy or history of malignancy in the past 5 years
- Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator
- Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the Physician would interfere with the anesthesia, treatment, or healing process)
- Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion)
- History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications
- Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen
- History of significant lymphatic drainage problems
- History of cancer which required lymph node biopsy or dissection
- Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions, hidradenitis, or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course
- History of keloid scarring, abnormal wound healing and / or prone to bruising
- History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders
- Use of isotretinoin (Accutane®) within 6 months of treatment or during the study
- Subject on systemic corticosteroid therapy 6 months prior to and throughout the course of the study
- Dysplastic nevi in the area to be treated
- Participation in a study of another device or drug within 3 month prior to enrollment or during this study, if treatments of cellulite were involved
- Subject has palpable lymphadenopathy at any visit. Standard palpation techniques will be used
- Subjects with history of severe edema
- As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: all subjects
Treatment with the ePrime radiofrequency microneedling device in the upper thighs and buttocks
|
The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in cellulite compared to baseline for the upper thighs and buttocks, as assessed by blinded evaluation of clinical photographs
Time Frame: Baseline and 3 months post treatment visit
|
Evaluate the efficacy of a single dermal and subcutaneous treatment with ePrime for the upper thighs and buttocks cellulite as assessed by blinded evaluators at 3 months post treatment visit.
|
Baseline and 3 months post treatment visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in cellulite compared to baseline for the upper thighs and buttocks, as assessed by blinded evaluation of clinical photographs
Time Frame: Baseline and 6 months post treatment visit
|
Evaluate the efficacy of a single dermal and subcutaneous treatment with ePrime for the upper thighs and buttocks cellulite as assessed by blinded evaluators at 6 months post treatment visit.
|
Baseline and 6 months post treatment visit
|
Number of Participants with Adverse Events
Time Frame: day 0 up to 7 months
|
evaluate the safety of a single dermal and subcutaneous treatment with ePrime for the upper thighs and buttocks cellulite at 1 week post treatment, 1 month, 3 and 6 months following the treatment.
|
day 0 up to 7 months
|
Improvement in cellulite compared to baseline
Time Frame: Baseline, 1 month, 3 and 6 months post treatment visit.
|
Improvement in cellulite compared to baseline, as assessed by study investigators, using Nurnberger-Muller scale at 1 month, 3 and 6 months post treatment visit.
|
Baseline, 1 month, 3 and 6 months post treatment visit.
|
Investigator satisfaction - by questionnaire
Time Frame: 1, 3, and 6 months post-treatment visit
|
Evaluate Investigator satisfaction at 1, 3, and 6 months post-treatment visit, using a satisfaction scale
|
1, 3, and 6 months post-treatment visit
|
Subject satisfaction - by questionnaire
Time Frame: 1, 3, and 6 months post-treatment visit
|
Evaluate subject satisfaction at 1, 3, and 6 months post-treatment visit, using a satisfaction scale
|
1, 3, and 6 months post-treatment visit
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Macrene Alexiades, MD, Dermatology and Laser Surgery Center 955 Park Avenue, New York, NY, 10028
- Principal Investigator: Leyda Bowes, MD, Bowes Dermatology, 3659 South Miami Avenue, Suite # 6008, Miami, FL 33133
- Principal Investigator: David Goldberg, MD, Skin Laser & Surgery Specialist of NY/NJ
- Principal Investigator: Girish Munavalli, MD, Laser & Vein Specialists of the Carolinas, 1918 Randolph Road, Suite 550, Charlotte, NC 28270
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DHF15911
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cellulite
-
Endo PharmaceuticalsCompletedEdematous Fibrosclerotic Panniculopathy (Cellulite)United States
-
Galderma R&DCompletedCellulite of the ButtocksBrazil
-
DSM Nutritional Products, Inc.TerminatedCellulite (Orange Peel Skin)Brazil
-
Nutrasource Pharmaceutical and Nutraceutical Services...Completed
-
InMode MD Ltd.Completed
-
Syneron MedicalTerminatedCircumference Reduction | Cellulite ReductionUnited States
-
Cairo UniversityNot yet recruitingEfficacy of Treatment of Cellulite Using Carboxy Therapy
-
Cutera Inc.CompletedTreatment for Cellulite on the Stomach and FlanksUnited States
-
Endo PharmaceuticalsCompletedEdematous Fibrosclerotic Panniculopathy (Cellulite)United States
-
Zeltiq AestheticsActive, not recruiting
Clinical Trials on ePrime
-
University of LeedsThe Leeds Teaching Hospitals NHS Trust; Yorkshire Cancer Research; Airedale NHS... and other collaboratorsCompleted
-
University of LeedsThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS Foundation... and other collaboratorsCompleted
-
Northwestern UniversityActive, not recruiting